Abstract : A simple strategy for t h e facile synthesis of cyclic rapamycinpeptide hybrids is developed and t h e affinities of these synthetic hybrids for FKBPl2 a r e evaluated. The results prompted to undertake a system a t i c study on t h e optimum length of the peptide cassette required for locking t h e binding domain of rapamycin in t h e specific conformation as present in i t s FKBP12-bound crystal structure. This led to t h e development of a high affinity FKBPl2 ligand.
(3) etc., a r e of dual-domain nature which poses significant challenge to structure-based design of analogous ligands . These immunosuppressants a r e possibly mimicking some endogenous peptidal substances which made us interested in designing and synthesizing cyclic peptidebased analogs of these natural products. These cyclic analogs will possess t h e binding domain of raparnycin, CI-C17 segment whose t w o ends will be stitched to a suitable peptide-based effector domain. To start with we planned to use the effector domain of cyclosporin MeLeuVal-MeLeu-Ala (residues 4-7)* in order to construct a bridging ligand 4 to bring FKBP12
and calcineurin together. Though it was understood t h a t neither t h e binding domain of rapamycin nor t h e effector domain of cyclosporin would possibly retain their parent geometry
The work presented was carried out at Sandoz Pharma Ltd., Basel in this hybrid structure, t h e effort was thought worthwhile because t h e chemistry developed in t h e process could eventually lead to designing more efficient analogs.
A number of acyclic ligands (6a-f) were synthesized3 first to search for the most suitable amino acid to replace t h e cyclohexyl moiety (Scheme I). The starting material for t h e syntheses of all these ligands was t h e benzyl e s t e r 5, itself synthesized in two simple steps from r a p a m y d n . Hydrogenation of 5 followed by coupling with respective C-terminalprotected amino acids gave t h e desired analogs 6a-d5a. The binding studies of these ligands with FKBPl2 (Table I) showed very weak binding for all of them. This was probably due to the greater entropic cost of binding such conformationally flexible acyclic molecules.
Anyway, f r o m t h e IC50 values it was decided to have a D-amino acid to replace t h e cyclohexyl moiety.
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The syntheses of the cyclic analogs also s t a r t e d with 5 (Scheme 11). Diastereoselective reduction of t h e methyl keto in 5 with lithium selectride at -78" gave a single product 73, in 96% yield. Silylation of 7 with TMS-triflate followed by t r e a t m e n t with dilute acid gave the hemiketal-protected methyl carbinol 8 as a mixture (ca. 1:I) of t w o diastereomers Scheme 11. Synthesis of the cyclic analog 4a (92% yield). The mixture was then coupled with the peptide chain Cbz-D-Phe-MeLeu-Val-M e L e~-A l a -o H~~ using D C C a n d catalytic amount of DMAP in CHZC12 at -10°C t o avoid any possible e p i m e r i~a t i o n~ (82% yield based on recovered starting material). The resulting e s t e r 9, as a mixture of diastereomers, was hydrogenated and subjected to macrolactamization using BOP-reagent to g e t 45% yield of t h e desired cyclic product. Finally facile desilylation of t h e hemiketal hydroxyl furnished t h e cyclic analog 4 a in 92% yield as a mixture 3 of rotamers (ca. 1:l in DMSO). Following t h e s a m e chemistry t h e D-Tyr-bearing analog 4b was also synthesized. The peptide fragment used in this case was Cbz-D-Tyr(Bz1)-MeLeu5b Val-MeLeu-Ala-OH .
The binding of t h e s e cyclic analogs 4a and 4b (Table I) did not show any dramatic improvement in their binding with FKBP12. In order to find o u t t h e ,reason for such weak binding, a detailed theoretical study was undertaken. The energy minimized structure of 8 9 4a was superimposed on rapamycin in its FKBP12 bound X-ray structure . MD simulation was then carried out on the assembly comprising of 4a, FKBP12 and 53 water molecules present in t h e X-ray structure for 20 ps during which t i m e 20 f r a m e s were sampled at equal intervals and e a c h f r a m e was minimized using conjugate gradients. The resulting twenty minimized structures were then superimposed as shown in Figure I . This shows considerable deviations in t h e binding domain geometry during t h e simulation process which was due to t h e increased flexibility associated with the larger ring size. This large distortion in t h e binding domain conformation of 4a explains why it showed a weak affinity for FKBP12. When the s a m e exercise was carried out with rapamycin bound to FKBP12 ( Figure   I ), t h e binding domain conformation did not change at all during t h e whole simulation process, which was not surprising since rapamycin-FKBPl2 X-ray structure was taken as t h e starting geometry which did not change much during a 20 ps MD simulation. and 53 w a t e r molecules present in t h e FKBPl2-rapamycin crystal structure. For clarity FKBPl2 a n d water molecules a r e not shown.
This led us to believe t h a t t h e conformation of t h e binding domain of rapamycin as present in its FKBP12 found X-ray structure should be targeted as a n ideal conformation in order to achieve maximum binding with FKBPI2. A systematic search was thus undertaken to find out t h e optimum chain length of t h e peptide cassette required to lock t h e binding domain in t h e desired conformation which was believed to be dependent on t h e ring size of these cyclic peptide-based analogs.
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This finally led to t h e development of a n excellent ligand 10 whose affinity for FKBP12 (IC50=9.6 nM) was almost comparable to those of natural products. The details of t h a t study will be reported elsewhere.
